{"id":2849,"date":"2017-01-18T17:48:16","date_gmt":"2017-01-18T17:48:16","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=19822"},"modified":"2017-01-18T17:48:16","modified_gmt":"2017-01-18T17:48:16","slug":"axim-biotech-begins-clinical-trial-targeting-ibs","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/","title":{"rendered":"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]<\/p>\n

AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity.<\/span><\/em><\/h3>\n

AXIM\u00ae Biotechnologies announced this week that the company has entered clinical trials for irritable bowel syndrome or IBS with their CanChew\u00ae Plus CBD-infused chewing gum. CanChew\u00ae Plus is AXIM\u00ae\u2019s patented delayed release delivery system for cannabinoids like CBD. <\/span><\/p>\n

In discussing the clinical trials, Medical Marijuana, Inc. CEO <\/span>Dr. Stuart Titus<\/span><\/a> stated, \u201cWe are thrilled to have a cannabinoid based application that may treat many disorders, including IBS which is now under clinical development. We are certainly excited to announce that we are in such clinical trials and attempting to put the science on top of the anecdotal evidence supporting efficacy in these conditions.\u201d<\/span><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=”19826″ img_size=”full”][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Research will be completed at the Wageningen University in the Netherlands. The company received approval<\/a> in December from the Medical Ethical Committee (METC) of Wageningen University, located in The Netherlands, to begin a study on patients suffering from irritable bowel syndrome (IBS) featuring its CanChew\u00ae Plus CBD gum.<\/p>\n

\u201cWe are pleased to have reached another milestone in the development of AXIM products to treat challenging health conditions,\u201d said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM\u00ae Biotech.<\/p>\n

Dr. Anastassov continued, \u201cIBS is the most common functional gastrointestinal disorder affecting 9-23% of the worldwide population, and it has no sustainable cure. The clinical trial at Wageningen University is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum, and we look forward to sharing updates from the trial with you. With positive outcome from the IBS clinical trial, we are ready to proceed immediately with further trials on our pharmaceutical grade CanChew Rx\u2122 products to treat inflammatory bowel disease (IBD); Ulcerative colitis and Crohn\u2019s disease. We are committed to finding research based cannabinoid solutions to help people suffering from gastrointestinal disorders and other health conditions with no effective remedies.\u201d<\/p>\n

The METC at Wageningen University, an institutional approval board that is compliant with the Ethical Principles for Medical Research, is responsible for reviewing and approving applications for clinical studies to be performed at the school. According to the Times Higher Education World University Rankings, Wageningen is the top university in The Netherlands<\/a>.<\/p>\n

Following successful PK\/PD trials to test possible effective dosing, AXIM\u00ae Biotechnologies will be testing a 50 mg dose of CBD per piece of chewing gum in the Phase II clinical trial.<\/p>\n

In discussing the data collected during these PK\/PD trials, Dr. Anastassov remarked, \u201cThese results show that excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an easy-to-use solution. We believe that we can match or improve the bioavailability profile for CBD compared to other delivery systems such as smoking or oral intake. We look forward to entering clinical trials and making available our cannabis-based medicinal solutions to patients suffering from IBS and other gastrointestinal disorders as soon as possible.\u201d<\/p>\n

The terms of the clinical trial allows patients up to 6 doses of 50 mg a day to control their symptoms of IBS, such as stomach cramps, bloating, and pain. The clinical trial will include 40 patients, aged from 18-65, who have been diagnosed with IBS according to ROME III criteria<\/a>, which includes abdominal pain that occurs at least three times a month for three months and a change in stool frequency or consistency.<\/p>\n

IBS is a chronic condition that requires long-term management. The condition\u2019s impact on a patient\u2019s overall quality of life may be the most significant complication, leading to a demand for effective treatments to ease the suffering of affected patients.<\/span><\/p>\n

\u201cIBS is a very common and often painful disorder which is still difficult to manage. People often experience sudden flare-ups and for many it has a negative impact on their quality of life. CBD has shown to have promising effects, but there has been a clear need for practical and effective formulations. Providing it via a chewing gum results in sustained release of the compound and better bio-availability\u201d said Renger Witkamp, Professor and Chair in Nutrition and Pharmacology of Wageningen University.<\/span><\/p>\n

It is unknown what exactly causes IBS. Some experts believe it is linked to issues with communication between the brain and the digestive tract, speeding up or slowing down the movement of stool through the intestine. Symptoms can be triggered by factors like diet, stress, hormonal changes, some medicines, and infections of the digestive tract. <\/span><\/p>\n

An estimated <\/span>15%<\/span><\/a> of the population worldwide suffers from IBS. In developed countries, that number jumps up to <\/span>25%<\/span><\/a> of the population, with women under 50 being affected at higher rates than any other group.<\/span><\/p>\n

It is difficult, however, to determine exact incidence rates since the IBS diagnosis rate is estimated to be less than <\/span>50%<\/span><\/a> in major markets. Approximately <\/span>40%<\/span><\/a> of all visits to gastroenterologists are due to IBS symptoms.<\/span><\/p>\n

Currently, IBS affects anywhere between <\/span>25 and 45 million<\/span><\/a> people in the United States. Already a significant segment of the healthcare market, the IBS market value in the United States is expected to continue to rise from <\/span>$589.6 million in 2013 to $1.5 billion by 2023<\/span><\/a>.<\/span><\/p>\n

The company\u2019s IBS study is just one of several clinical studies AXIM\u00ae Biotechnologies is looking to undertake. Earlier in the year, AXIM\u00ae announced that it had <\/span>secured the necessary funding<\/span><\/a> to move forward with a group of cannabinoid-based clinical trials, including trials on its MedChew\u00ae RX, CanChew\u00ae Plus, and AX-1602 topically applied cannabinoid ointment. The company also published a <\/span>development pipeline chart<\/span><\/a> to reveal their new drug schedule for the coming months and years.<\/span><\/p>\n

Keep up to date with news from AXIM\u00ae Biotechnologies and other Medical Marijuana, Inc. investments by following <\/span>our news feed<\/span><\/a>.<\/span>[\/vc_column_text][\/vc_column][\/vc_row] \t<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text] AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity. AXIM\u00ae Biotechnologies announced this week that the company has entered clinical trials for irritable bowel syndrome or IBS with their CanChew\u00ae Plus CBD-infused chewing gum. CanChew\u00ae Plus is AXIM\u00ae\u2019s patented delayed release delivery system […]<\/p>\n","protected":false},"author":1,"featured_media":211,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[160,3],"tags":[183],"class_list":["post-2849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-axim-biotechnologies","category-company-news","tag-axim-biotechnologies"],"yoast_head":"\nAXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment - Medical Marijuana, Inc.<\/title>\n<meta name=\"description\" content=\"AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment - Medical Marijuana, Inc.\" \/>\n<meta property=\"og:description\" content=\"AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/\" \/>\n<meta property=\"og:site_name\" content=\"Medical Marijuana, Inc.\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MJNAInc\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-18T17:48:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2017\/01\/mjna-blog-flask-in-scientist-hand-17-01-17-ver1-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adminTorusBrand\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@mjna_inc\" \/>\n<meta name=\"twitter:site\" content=\"@mjna_inc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminTorusBrand\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/\"},\"author\":{\"name\":\"adminTorusBrand\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c\"},\"headline\":\"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment\",\"datePublished\":\"2017-01-18T17:48:16+00:00\",\"dateModified\":\"2017-01-18T17:48:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/\"},\"wordCount\":1002,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#organization\"},\"keywords\":[\"AXIM Biotechnologies\"],\"articleSection\":[\"Axim Biotechnologies\",\"Company News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/\",\"url\":\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/\",\"name\":\"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment - Medical Marijuana, Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#website\"},\"datePublished\":\"2017-01-18T17:48:16+00:00\",\"dateModified\":\"2017-01-18T17:48:16+00:00\",\"description\":\"AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity.\",\"breadcrumb\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medicalmarijuanainc.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#website\",\"url\":\"https:\/\/medicalmarijuanainc.com\/\",\"name\":\"Medical Marijuana, Inc.\",\"description\":\"We are a company of firsts\u00ae\ufe0f. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space. Through its subsidiaries, Medical Marijuana, Inc. manufacturers and sells some of the best cannabidiol (CBD), and other cannabinoid-based products, available!\",\"publisher\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medicalmarijuanainc.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#organization\",\"name\":\"Medical Marijuana, Inc.\",\"url\":\"https:\/\/medicalmarijuanainc.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png\",\"contentUrl\":\"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png\",\"width\":512,\"height\":512,\"caption\":\"Medical Marijuana, Inc.\"},\"image\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/MJNAInc\",\"https:\/\/twitter.com\/mjna_inc\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c\",\"name\":\"adminTorusBrand\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g\",\"caption\":\"adminTorusBrand\"},\"sameAs\":[\"https:\/\/medicalmarijuanainc.com\"],\"url\":\"https:\/\/medicalmarijuanainc.com\/author\/admintorusbrand\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment - Medical Marijuana, Inc.","description":"AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/","og_locale":"en_US","og_type":"article","og_title":"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment - Medical Marijuana, Inc.","og_description":"AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity.","og_url":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/","og_site_name":"Medical Marijuana, Inc.","article_publisher":"https:\/\/www.facebook.com\/MJNAInc","article_published_time":"2017-01-18T17:48:16+00:00","og_image":[{"width":1200,"height":500,"url":"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2017\/01\/mjna-blog-flask-in-scientist-hand-17-01-17-ver1-1.png","type":"image\/png"}],"author":"adminTorusBrand","twitter_card":"summary_large_image","twitter_creator":"@mjna_inc","twitter_site":"@mjna_inc","twitter_misc":{"Written by":"adminTorusBrand","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#article","isPartOf":{"@id":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/"},"author":{"name":"adminTorusBrand","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c"},"headline":"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment","datePublished":"2017-01-18T17:48:16+00:00","dateModified":"2017-01-18T17:48:16+00:00","mainEntityOfPage":{"@id":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/"},"wordCount":1002,"commentCount":0,"publisher":{"@id":"https:\/\/medicalmarijuanainc.com\/#organization"},"keywords":["AXIM Biotechnologies"],"articleSection":["Axim Biotechnologies","Company News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/","url":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/","name":"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment - Medical Marijuana, Inc.","isPartOf":{"@id":"https:\/\/medicalmarijuanainc.com\/#website"},"datePublished":"2017-01-18T17:48:16+00:00","dateModified":"2017-01-18T17:48:16+00:00","description":"AXIM\u00ae Biotechnologies Brings Their Patented CanChew\u00ae Plus Delayed-Release CBD Chewing Gum to Clinical Trials for IBS, a $1.5B market opportunity.","breadcrumb":{"@id":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/medicalmarijuanainc.com\/2017\/01\/18\/axim-biotech-begins-clinical-trial-targeting-ibs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medicalmarijuanainc.com\/"},{"@type":"ListItem","position":2,"name":"AXIM\u00ae Biotech Begins Clinical Trial Targeting Effective Irritable Bowel Syndrome Treatment"}]},{"@type":"WebSite","@id":"https:\/\/medicalmarijuanainc.com\/#website","url":"https:\/\/medicalmarijuanainc.com\/","name":"Medical Marijuana, Inc.","description":"We are a company of firsts\u00ae\ufe0f. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space. Through its subsidiaries, Medical Marijuana, Inc. manufacturers and sells some of the best cannabidiol (CBD), and other cannabinoid-based products, available!","publisher":{"@id":"https:\/\/medicalmarijuanainc.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medicalmarijuanainc.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/medicalmarijuanainc.com\/#organization","name":"Medical Marijuana, Inc.","url":"https:\/\/medicalmarijuanainc.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/","url":"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png","contentUrl":"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png","width":512,"height":512,"caption":"Medical Marijuana, Inc."},"image":{"@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MJNAInc","https:\/\/twitter.com\/mjna_inc"]},{"@type":"Person","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c","name":"adminTorusBrand","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g","caption":"adminTorusBrand"},"sameAs":["https:\/\/medicalmarijuanainc.com"],"url":"https:\/\/medicalmarijuanainc.com\/author\/admintorusbrand\/"}]}},"_links":{"self":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/posts\/2849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/comments?post=2849"}],"version-history":[{"count":0,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/posts\/2849\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/media\/211"}],"wp:attachment":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/media?parent=2849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/categories?post=2849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/tags?post=2849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}